Invasive Fungal Infections in Children with Acute Leukemia: Epidemiology, Risk Factors, and Outcome.

acute leukemia children invasive fungal infections risk factors

Journal

Microorganisms
ISSN: 2076-2607
Titre abrégé: Microorganisms
Pays: Switzerland
ID NLM: 101625893

Informations de publication

Date de publication:
11 Jan 2024
Historique:
received: 18 12 2023
revised: 08 01 2024
accepted: 09 01 2024
medline: 23 1 2024
pubmed: 23 1 2024
entrez: 23 1 2024
Statut: epublish

Résumé

Invasive fungal infections (IFI) cause morbidity and mortality in children with acute leukemia (AL). We retrospectively collected data on febrile neutropenic episodes (FNE) in AL children (2016-2021) and assessed factors associated with proven/probable IFI. Ninety-three children developed 339 FNE. Seventeen (18.3%) children developed 19 proven/probable IFI (11 yeast; eight molds). The proven/probable yeast IFI rate was 6/52 (11.5%) in children who belong to the high risk for IFI category (HR-IFI-AL: high-risk acute lymphocytic leukemia (ALL), acute myeloid leukemia, relapse); and 5/41 (12.2%) in the non-HR-IFI-AL category (standard/intermediate risk ALL). The proven/probable mold IFI rate was 7/52 (13.5%) in HR-IFI-AL children and 1/41 (2.4%) in the non-HR-IFI-AL category. In the multivariable analysis, underlying genetic syndrome, oral mucositis, and older age were significantly associated with proven/probable IFI, while a longer time since AL diagnosis was protective. Two of 13 (15.4%) HR-IFI-AL children died because of IFI. The elevated risks of proven/probable mold IFI and the associated mortality in HR-IFI-AL children, and high risk of invasive candidiasis in the non-HR-IFI-AL group, emphasize the need for the close monitoring of local epidemiology and the adjustment of practices accordingly.

Identifiants

pubmed: 38257971
pii: microorganisms12010145
doi: 10.3390/microorganisms12010145
pii:
doi:

Types de publication

Journal Article

Langues

eng

Auteurs

Tamar Ruth Gal Etzioni (TR)

Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel.
Pediatric Division, Hadassah Medical Center, Jerusalem 91120, Israel.

Nurit Fainshtain (N)

Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel.
Pediatric Division, Hadassah Medical Center, Jerusalem 91120, Israel.

Adi Nitzan-Luques (A)

Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel.
Pediatric Division, Hadassah Medical Center, Jerusalem 91120, Israel.
The Dyna & Fala Weinstock Department of Pediatric Hematology Oncology, Hadassah Medical Center, Jerusalem 91120, Israel.

Gal Goldstein (G)

Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel.
Pediatric Division, Hadassah Medical Center, Jerusalem 91120, Israel.
The Dyna & Fala Weinstock Department of Pediatric Hematology Oncology, Hadassah Medical Center, Jerusalem 91120, Israel.

Sigal Weinreb (S)

Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel.
Pediatric Division, Hadassah Medical Center, Jerusalem 91120, Israel.
The Dyna & Fala Weinstock Department of Pediatric Hematology Oncology, Hadassah Medical Center, Jerusalem 91120, Israel.

Violeta Temper (V)

Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel.
Department of Microbiology and Infectious Diseases, Hadassah Medical Center, Jerusalem 91120, Israel.

Maya Korem (M)

Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel.
Department of Microbiology and Infectious Diseases, Hadassah Medical Center, Jerusalem 91120, Israel.

Dina Averbuch (D)

Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel.
Pediatric Division, Hadassah Medical Center, Jerusalem 91120, Israel.
Pediatric Infectious Diseases, Hadassah Medical Center, Jerusalem 91120, Israel.

Classifications MeSH